XML 68 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense The following table presents share-based compensation expense:
YearShare-Based
Compensation
Expense
Tax Benefit
2018$44.7 $11.2 
201949.9 8.2 
202067.4 10.3 
Schedule of Transactions in the Company's Restricted Stock Restricted StockThe following table summarizes transactions in the Company’s restricted stock units:
Restricted
Stock Units
Weighted
Average
Grant Date
Value
Unvested units—December 31, 20191.1 $123.70 
Units granted0.4 73.75 
Units vested(0.4)141.67 
Units forfeited(0.0)134.52 
Performance condition changes0.1 105.92 
Unvested units—December 31, 20201.2 99.46 
Schedule of Transactions in the Company's Stock Options The following table summarizes transactions in the Company’s stock options:
Stock 
Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life (Years)
Unexercised options outstanding—December 31, 20192.3 $85.58  
Options granted0.2 74.31  
Options exercised(0.0)86.78  
Options forfeited(0.0)147.77  
Performance condition changes0.4 74.42 
Unexercised options outstanding—December 31, 20202.9 82.14 5.1
Exercisable at December 31, 20200.4 126.95 1.7
Schedule of Assumptions Used to Determine Fair Value of Options Granted The weighted average grant date assumptions used to estimate the fair value of stock options granted were as follows:
 For the Years Ended December 31,
 201820192020
Dividend yield0.8 %1.7 %1.6 %
Expected volatility(1)
25.5 %29.4 %30.5 %
Risk-free interest rate(2)
2.8 %1.5 %0.9 %
Expected life of stock options (in years)(3)
5.75.75.7
Forfeiture rate0.0 %0.0 %0.0 %
__________________________
(1)Expected volatility is based on historical and implied volatility.
(2)Risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant.
(3)Expected life of options (in years) is based on the Company’s historical and expected exercise behavior.